Successful Transcathether Treatment Of A Degenerated Sutureless Valve Using An Self-expandable Acurate Neo 2 Heart Valve
Jan Rychter1, Ali Aidibi2, Krystian Jakimowicz2, Roch Pakuła1, Tomasz Niklewski2, Michał Hawranek3, Mariusz Gąsior3, Michał Zembala2.
1Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Medical University of Silesia in Katowice, Silesian Centre for Heart Diseases, Zabrze, Poland, 2Department of Cardiac Surgery, Heart and Lung Transplantation and Mechanical Circulatory Support, Silesian Centre for Heart Diseases, Zabrze, Poland, 33rd Department of Cardiology, Medical University of Silesia in Katowice, Silesian Centre for Heart Diseases, Zabrze, Poland.
Background: Valve-in-valve (VinV) implantation is an great alternative to reoperation for patients with degenerated bioprostheses and became a method of choice in treatment of bioprosthetic valve degeneration when surgical intervention is associated with increased risk of peri- and postoperative complications. In this case report we describe successful implantation of the Acurate Neo 2 TF transcatheter valve (Boston Scientific, Marlborough, Massachusetts) into a failed sutureless aortic bioprosthesis - Perceval S surgical valve (LivaNova, London, United Kingdom).
Methods: 82-year-old man nine years ago had received a Liva Nova Perceval S (25mm) sutureless valve due to severe aortic valve stenosis. Current transthoracic echocardiographic assessment revealed severe degenerative changes of valvular prosthesis with severe aortic regurgitation and good ejection fraction 60%. Coronarography showed no significant narrowings in coronary arteries. After reevaluation heart team decision was to made valve-in-valve transcatheter aortic valve implantation.
Results: The operation was performed under local anesthesia with standard hemodynamic monitoring. We successfully implanted Acurate Neo 2 size M prosthesis from transfemoral approach. Post procedural echocardiography revealed good function of Acurate neo prosthesis with mean gradient 10 mmHg and no paravalvular leak. Three days later the patient was discharged home following uneventful recovery.
Conclusions: The case demonstrates that not only suture-based stented and stentless bioprostheses can be treated by a valve in valve strategy, but it is also feasible to treat a failed sutureless valve using an self-expandable Acurate neo 2 prosthesis.
Back to 2022 Display ePosters